MCID: ACR014
MIFTS: 42

Acral Lentiginous Melanoma malady

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

About this section

Aliases & Descriptions for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 10 45 12
Acral Lentiginous Malignant Melanoma of Skin 45
Acral Lentiginous Melanoma, Malignant 10
Acral Lentiginous Malignant Melanoma 65
 
Malignant Acral Lentiginous Melanoma 10
Palmar/plantar Melanoma 45
Subungual Melanoma 45
Alm 45

Classifications:



External Ids:

Disease Ontology10 DOID:6367
UMLS65 C0346037

Summaries for Acral Lentiginous Melanoma

About this section
Disease Ontology:10 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

MalaCards based summary: Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to hepatocellular carcinoma and colorectal cancer. An important gene associated with Acral Lentiginous Melanoma is NRAS (Neuroblastoma RAS Viral Oncogene Homolog), and among its related pathways are Thyroid cancer and MAP2K and MAPK activation. Affiliated tissues include skin, endothelial and prostate, and related mouse phenotypes are limbs/digits/tail and craniofacial.

Wikipedia:68 Acral lentiginous melanoma is a kind of lentiginous skin melanoma. Melanoma is a potentially serious... more...

Related Diseases for Acral Lentiginous Melanoma

About this section

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to acral lentiginous melanoma

Symptoms for Acral Lentiginous Melanoma

About this section

Drugs & Therapeutics for Acral Lentiginous Melanoma

About this section

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DabrafenibapprovedPhase 27044462760, 44516822
Synonyms:
BRAF inhibitor GSK2118436
Dabrafenib
Dabrafenib Mesylate
 
GSK2118436
GSK2118436a
Tafinlar
dabrafenib
2
Dasatinibapproved, investigationalPhase 2268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
3
TrametinibapprovedPhase 2111871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
4
Sunitinibapproved, investigationalPhase 2486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
5
Maleic acidexperimentalPhase 2274110-16-7444972, 444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
6Imatinib MesylatePhase 2577123596
7Protein Kinase InhibitorsPhase 23162
8
CediranibPhase 2879933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
9Cyclin-Dependent Kinase Inhibitor ProteinsPhase 220
10Contraceptives, OralPhase 23734
11Angiogenesis InhibitorsPhase 23688
12Angiogenesis Modulating AgentsPhase 23611
13tyrosineNutraceuticalPhase 2596
14
Ganciclovirapproved, investigationalPhase 114082410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene IV
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir Sodium
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
15Nucleic Acid Synthesis InhibitorsPhase 13836
16Ganciclovir triphosphatePhase 1140
17Antiviral AgentsPhase 18071
18Anti-Infective AgentsPhase 117220

Interventional clinical trials:

(show all 13)
idNameStatusNCT IDPhase
1AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2
2Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2
3A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadRecruitingNCT01395121Phase 2
4Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryRecruitingNCT00700882Phase 2
5Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaRecruitingNCT02083354Phase 2
6SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaActive, not recruitingNCT00577382Phase 2
7Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingNCT00937937Phase 2
8Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaActive, not recruitingNCT01120275Phase 2
9Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaActive, not recruitingNCT00424515Phase 2
10Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaActive, not recruitingNCT00788775Phase 2
11Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaTerminatedNCT01092728Phase 2
12Gene Therapy and Ganciclovir in Treating Patients With Stage IV MelanomaCompletedNCT00005057Phase 1
13Study of Families With MelanomaRecruitingNCT00445783

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

About this section

Anatomical Context for Acral Lentiginous Melanoma

About this section

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

33
Skin, Endothelial, Prostate, Breast, Neutrophil, T cells, Monocytes

Animal Models for Acral Lentiginous Melanoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma:

38 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.7KIT, MET, NRAS, PTEN
2MP:00053828.5BRAF, KIT, MET, NRAS
3MP:00011868.5BRAF, CDKN2A, KIT, NRAS, PTEN
4MP:00107718.5BRAF, CDKN2A, KIT, NRAS, PTEN
5MP:00053898.3BRAF, CDKN2A, KIT, PTEN, TERT
6MP:00053888.0BRAF, CDKN2A, KIT, MET, PTEN
7MP:00053907.9BRAF, CDKN2A, KIT, PTEN, TERT
8MP:00053697.8BRAF, CDKN2A, KIT, MET, PTEN
9MP:00028737.7BRAF, KIT, MET, NRAS, PTEN, TERT
10MP:00053807.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN
11MP:00053707.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN
12MP:00053917.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
13MP:00053867.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
14MP:00036317.4BRAF, CDKN2A, KIT, MET, PTEN, TERT
15MP:00053977.3BRAF, CDKN2A, KIT, NRAS, PTEN, TERT
16MP:00053797.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
17MP:00020067.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
18MP:00053857.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
19MP:00053817.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
20MP:00053847.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
21MP:00053767.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
22MP:00107686.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
23MP:00053786.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
24MP:00053876.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN

Publications for Acral Lentiginous Melanoma

About this section

Articles related to Acral Lentiginous Melanoma:

(show top 50)    (show all 110)
idTitleAuthorsYear
1
Management of a case of recognized perforation of the globe during strabismus surgery. (25798703)
2015
2
Siglec-6 expression is increased in placentas from pregnancies complicated by preterm preeclampsia. (23171684)
2013
3
The difference of neovascularization in early intra-alveolar fibrosis between nonspecific interstitial pneumonia and usual interstitial pneumonia. (23714250)
2013
4
Assessing Social Anxiety in African American Youth using the Social Phobia and Anxiety Inventory for Children. (23872906)
2013
5
Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. (22939954)
2013
6
Association of Toll-like receptor 4 polymorphisms with diabetic foot ulcers and application of artificial neural network in DFU risk assessment in type 2 diabetes patients. (23936790)
2013
7
Intracardiac and intravenous leiomyomatosis. (23036637)
2012
8
Tuberculous arthritis of the knee joint mimicking pigmented villonodular synovitis. (21912886)
2012
9
Pathomorphological and immunohistochemical analysis of proliferative activity of the buccal mucosal epithelium in lichen planus. (23330144)
2012
10
Lipoxin Aa88 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. (21263017)
2011
11
A RING E3-substrate complex poised for ubiquitin-like protein transfer: structural insights into cullin-RING ligases. (21765416)
2011
12
Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. (21264446)
2011
13
Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. (20364400)
2010
14
Functional deficiencies of sulfite oxidase: Differential diagnoses in neonates presenting with intractable seizures and cystic encephalomalacia. (19793632)
2010
15
Bacterial vaginosis: are we coming full circle? (19863440)
2009
16
Oral pathology case #60. Case number 4. Florid cemento-osseous dysplasia. (18924275)
2008
17
PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. (18239155)
2008
18
Regulation of vascular function by RCAN1 (ADAPT78). (18294449)
2008
19
Fas (CD95) alters neuronal nitric oxide synthase expression to contribute in diabetic gastroparesis. (17161551)
2007
20
Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. (16949285)
2006
21
Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. (16820412)
2006
22
Conduct disorder-A sequelae of viral encephalitis. (20703348)
2006
23
The outcome of a preventive dental care programme on the prevalence of localized aggressive periodontitis in Down's syndrome individuals. (16774634)
2006
24
Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. (15378523)
2005
25
Long-term changes in visual acuity and refractive error in amblyopes. (15252350)
2004
26
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. (15078988)
2004
27
Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency. (12949894)
2003
28
Epidemiological, clinical and laboratory distinction between human granulocytic ehrlichiosis and the initial phase of tick-borne encephalitis. (12422617)
2002
29
Characterization of sperm protein 17 in human somatic and neoplastic tissue. (12213290)
2002
30
H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. (11867515)
2002
31
A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. (11830556)
2002
32
Fresh frozen plasma in the pediatric age group and in congenital coagulation factor deficiency. (12379290)
2002
33
Mutations of tyrosine 537 in the human estrogen receptor-alpha selectively alter the receptor's affinity for estradiol and the kinetics of the interaction. (11914066)
2002
34
Osmoregulation of vasopressin secretion via activation of neurohypophysial nerve terminals glycine receptors by glial taurine. (11549721)
2001
35
Meshy meningioma: a potential novel variant. (11666022)
2001
36
Dopamine D5 receptors of rat and human brain. (11036203)
2000
37
Psoriasin (S100A7) expression and invasive breast cancer. (10595935)
1999
38
Extrahepatic regional chemotherapy: use of technetium-99m labeled macroaggregated albumin. (10362345)
1999
39
Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining. (9819502)
1998
40
The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus. (9299627)
1997
41
Mutations of the MEN1 tumor suppressor gene in pituitary tumors. (9407947)
1997
42
Neutrophil and macrophage activation and anaphylatoxin formation in orthotopic liver transplantation without the use of veno-venous bypass. (8848927)
1996
43
Thornton-Griggs-Moxley disease: myotonic dystrophy type 2. (7979231)
1994
44
Renin gene polymorphism associated with aldosterone responsiveness to the renin-angiotensin system in patients with aldosterone-producing adenomas. (7915644)
1994
45
DNA target selectivity by the vitamin D3 receptor: mechanism of dimer binding to an asymmetric repeat element. (8392196)
1993
46
Nuclear protein binding to octamer motifs in the immunoglobulin gamma 1 switch region. (2025612)
1991
47
Dopamine-induced homologous and heterologous desensitizations of adenylate cyclase-coupled receptors on striatal neurons. (2177700)
1990
48
Surgical management of advanced hemophilic arthropathy. An overview of 20 years' experience. (2650951)
1989
49
Vascular effects of photodynamic therapy in an intraocular retinoblastoma-like tumour. (2590545)
1989
50
Effect of stanozolol in patients with pityriasis rubra pilaris and retinol-binding protein deficiency. (7199120)
1982

Variations for Acral Lentiginous Melanoma

About this section

Cosmic variations for Acral Lentiginous Melanoma:

7 (show top 50)    (show all 766)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM476BRAFskin,acral,malignant melanoma,acral lentiginous3
2COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
3COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
4COSM476BRAFskin,acral,malignant melanoma,NS3
5COSM476BRAFskin,acral,malignant melanoma,NS3
6COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
7COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
8COSM476BRAFskin,acral,malignant melanoma,NS3
9COSM476BRAFskin,acral,malignant melanoma,NS3
10COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
11COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
12COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
13COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
14COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
15COSM476BRAFskin,acral,malignant melanoma,acral lentiginous3
16COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
17COSM476BRAFskin,acral,malignant melanoma,NS3
18COSM476BRAFskin,acral,malignant melanoma,NS3
19COSM476BRAFskin,acral,malignant melanoma,NS3
20COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
21COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
22COSM476BRAFskin,acral,malignant melanoma,NS3
23COSM476BRAFskin,acral,malignant melanoma,NS3
24COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
25COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
26COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
27COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
28COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
29COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
30COSM476BRAFskin,acral,malignant melanoma,NS3
31COSM476BRAFskin,acral,malignant melanoma,acral lentiginous3
32COSM476BRAFskin,acral,malignant melanoma,NS3
33COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
34COSM476BRAFskin,acral,malignant melanoma,NS3
35COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
36COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
37COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
38COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
39COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
40COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
41COSM476BRAFskin,acral,malignant melanoma,NS3
42COSM476BRAFskin,acral,malignant melanoma,NS3
43COSM476BRAFskin,acral,malignant melanoma,NS3
44COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
45COSM476BRAFskin,NS,malignant melanoma,acral lentiginous3
46COSM476BRAFskin,acral,malignant melanoma,NS3
47COSM476BRAFskin,acral,malignant melanoma,NS3
48COSM476BRAFskin,acral,malignant melanoma,NS3
49COSM476BRAFskin,acral,malignant melanoma,NS3
50COSM460BRAFskin,acral,malignant melanoma,acral lentiginous3

Expression for genes affiliated with Acral Lentiginous Melanoma

About this section
Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for genes affiliated with Acral Lentiginous Melanoma

About this section

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
19.6BRAF, NRAS
29.6BRAF, NRAS
39.6BRAF, NRAS
49.6BRAF, NRAS
5
Show member pathways
9.2BRAF, NRAS
69.1CDKN2A, NRAS, TERT
7
Show member pathways
9.1BRAF, CDKN2A, NRAS
89.1BRAF, CDKN2A, NRAS
9
Show member pathways
9.0BRAF, NRAS, PTEN
108.8BRAF, CDKN2A, PTEN
118.8BRAF, MET, NRAS
12
Show member pathways
8.5BRAF, KIT, NRAS, PTEN
13
Show member pathways
8.5BRAF, MET, PTEN
14
Show member pathways
8.5BRAF, MET, PTEN
158.4BRAF, CDKN2A, NRAS, PTEN
16
Show member pathways
8.3BRAF, KIT, MET, NRAS
17
Show member pathways
8.3BRAF, KIT, MET, NRAS
188.2KIT, MET, NRAS, PTEN
198.2KIT, MET, NRAS, PTEN
208.1CDKN2A, MET, NRAS, PTEN
21
Show member pathways
8.1BRAF, MET, NRAS, PTEN
22
Show member pathways
8.1BRAF, MET, NRAS, PTEN
23
Show member pathways
8.1BRAF, MET, NRAS, PTEN
24
Show member pathways
7.7BRAF, KIT, MET, NRAS, PTEN
25
Show member pathways
7.6BRAF, CDKN2A, MET, NRAS, PTEN
26
Show member pathways
7.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
277.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
28
Show member pathways
6.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN

GO Terms for genes affiliated with Acral Lentiginous Melanoma

About this section

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.2BRAF, KIT
2somatic stem cell divisionGO:004810310.1CDKN2A, KIT
3regulation of axon regenerationGO:004867910.0BRAF, PTEN
4somatic stem cell population maintenanceGO:003501910.0BRAF, KIT
5replicative senescenceGO:00903999.8CDKN2A, TERT
6activation of MAPKK activityGO:00001869.5BRAF, KIT, NRAS
7vascular endothelial growth factor receptor signaling pathwayGO:00480109.5BRAF, KIT, NRAS
8insulin receptor signaling pathwayGO:00082869.5BRAF, KIT, NRAS
9regulation of protein stabilityGO:00316479.4CDKN2A, PTEN, TERT
10long-term synaptic potentiationGO:00602919.2BRAF, PTEN
11fibroblast growth factor receptor signaling pathwayGO:00085439.0BRAF, KIT, NRAS, PTEN
12neurotrophin TRK receptor signaling pathwayGO:00480119.0BRAF, NRAS, PTEN
13axon guidanceGO:00074118.8BRAF, KIT, MET
14innate immune responseGO:00450878.5BRAF, KIT, NRAS, PTEN
15signal transductionGO:00071658.0BRAF, KIT, MET, NRAS

Sources for Acral Lentiginous Melanoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet